| Title |
|
|
|
New-generation drug-eluting stents : focus on Xience V® everolimus-eluting stent and Resolute® zotarolimus-eluting stent
| |
| Author |
|
|
|
| |
| Abstract |
|
|
|
| Compared to bare metal stent angioplasty, first-generation drug-eluting stents (DES) have markedly reduced the incidence of in-stent restenosis. However, given the increased concerns over late and very late stent thrombosis, newer-generation DES were developed. To date, these DES have virtually replaced the use of first-generation DES worldwide. In this review article, we carefully consider the pre-clinical and clinical trials that have been performed with currently available, european conformity-marked and Food and Drug Administration-approved new-generation Resolute (R) and Xience V (R) DES. (J Interven Cardiol 2013;26:278-286) | | |
| Language |
|
|
|
English
| |
| Source (journal) |
|
|
|
Journal of interventional cardiology. - Mount Kisco, N.Y. | |
| Publication |
|
|
|
Mount Kisco, N.Y. : 2013
| |
| ISSN |
|
|
|
0896-4327
| |
| Volume/pages |
|
|
|
26:3(2013), p. 278-286
| |
| ISI |
|
|
|
000320173700010
| |
| Full text (Publisher's DOI) |
|
|
| | |
| Full text (publisher's version - intranet only) |
|
|
| | |
|